Tafenoquine
- Generic Name
- Tafenoquine
- Brand Names
- Arakoda, Krintafel
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28F3N3O3
- CAS Number
- 106635-80-7
- Unique Ingredient Identifier
- 262P8GS9L9
- Background
Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoquine was further developed collaboratively between Glaxo...
- Indication
用于16岁及以上疟疾患者，根治(预防复发)由间日疟原虫(P.vivax)导致的疟疾。
- Associated Conditions
- Malaria caused by plasmodium vivax
- Associated Therapies
- -
Southeast Asia Dose Optimization of Tafenoquine
- Conditions
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 700
- Registration Number
- NCT04704999
- Locations
- 🇱🇦
Lao Oxford Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
🇻🇳Oxford University Clinical Research Unit (OUCRU), Binh Phuoc, Vietnam
🇰🇭Mahidol Oxford Tropical Medicine Research Unit (MORU), Cambodia, Siem Reap, Cambodia
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Menzies School of Health Research
- Target Recruit Count
- 960
- Registration Number
- NCT04411836
- Locations
- 🇵🇰
Aga Khan Hospital Karachi, Karachi, Pakistan
🇰🇭Kravanh District Hospital, Pursat, Pursat Province, Cambodia
🇰🇭Siem Pang Health Centre, Stung Treng, Cambodia
Long-Term Safety Study of Tafenoquine
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- 60 Degrees Pharmaceuticals LLC
- Target Recruit Count
- 600
- Registration Number
- NCT03320174
- Locations
- 🇺🇸
Valley Retina Institute, McAllen, Texas, United States
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
🇺🇸Retina Consultants of Southern Colorado, Colorado Springs, Colorado, United States
Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT02802501
- Locations
- 🇮🇩
GSK Investigational Site, Jakarta, Indonesia
A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT02563496
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam
Evaluation of Weekly Tafenoquine
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2018-09-13
- Target Recruit Count
- 249
- Registration Number
- NCT02491606
An Evaluation of Weekly Tafenoquine
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2017-05-30
- Target Recruit Count
- 306
- Registration Number
- NCT02488980
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
- Conditions
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 251
- Registration Number
- NCT02216123
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam
A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate
- Conditions
- Interventions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT02184637
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults
- Conditions
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2018-02-23
- Target Recruit Count
- 70
- Registration Number
- NCT01290601
- Locations
- 🇹🇭
Bangkok Hospital for Tropical Diseases/Mahidol University, Bangkok, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.